Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 271 to 285 of 288 results for back pain

  1. Head injury (QS74)

    This quality standard covers assessment, early management and rehabilitation following head injury in adults, young people and children. It describes high-quality care in priority areas for improvement.

  2. Pembrolizumab for advanced melanoma not previously treated with ipilimumab (TA366)

    Evidence-based recommendations on pembrolizumab (Keytruda) for treating advanced melanoma in adults who have not had ipilimumab.

  3. Trauma (QS166)

    This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.

  4. Overweight and obesity management (NG246)

    This guideline covers the prevention and management of overweight, obesity and central adiposity in children, young people and adults. It brings together and updates all NICE's previous guidelines on overweight and obesity. It does not cover pregnancy.

  5. Motor neurone disease: assessment and management (NG42)

    This guideline covers assessing and managing motor neurone disease (MND). It aims to improve care from the time of diagnosis, and covers information and support, organisation of care, managing symptoms and preparing for end of life care.

  6. The social care guidance manual (PMG10)

    This manual explains how NICE develops and updates social care guidance. It provides advice on the technical aspects of guidance development and the methods used

  7. ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot (MIB56)

    NICE has developed a medtech innovation briefing (MIB) on the ODFS Pace and Pace XL functional electrical stimulation devices for treating drop foot

  8. Guide to the processes of technology appraisal (PMG19)

    This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes

  9. Developing NICE guidelines: the manual (PMG20)

    This manual explains the processes and methods used to develop and update NICE guidelines, the guidance that NICE develops covering topics across clinical care (in primary, secondary and community care settings), social care and public health. For more information on the other types of NICE guidance and advice (including technology appraisal guidance), see about NICE

  10. Methods for the development of NICE public health guidance (third edition) (PMG4)

    This manual describes the methods used by the Centre for Public Health Excellence (CPHE) in NICE to develop and update public health guidance

  11. Breakthrough life-extending combination treatment for advanced bladder cancer recommended by NICE

    The new treatment offers hope to thousands living with advanced urothelial cancer, with clinical trials showing overall survival rates were almost twice as long compared to standard treatment.

  12. Up to 1,000 women a year could benefit from new at-home treatment for endometriosis

    Today we've recommended a new treatment option for symptoms of endometriosis that can be taken at home.

  13. Hundreds of people in England to benefit from take-at-home tablet bladder cancer treatment

    Today, for the first time, we have given the green light to a targeted treatment for the most common form of bladder cancer.

  14. Thousands could benefit from new option for treating symptoms of uterine fibroids

    As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.

  15. NICE has made six times more lung cancer treatment recomendations over the past ten years than in the previous decade

    We have also recommended osimertinib for routine use on the NHS today.